Rosenstock J, et al. - In uncontrolled type 2 diabetes, researchers tested the safety and effectiveness of triple therapy with low-dose dapagliflozin plus saxagliptin added to metformin. For this investigation, 883 patients (HbA1c 7.5–10.0%) on metformin ≥1500 mg/day were randomized to add-on dapagliflozin 5 mg/day plus saxagliptin 5 mg/day or to add-on of either one of these. According to this 24-week, double-blind trial, triple therapy significantly lowered fasting plasma glucose and body weight and β-hydroxybutyrate levels were lower vs dapagliflozin plus metformin. In uncontrolled type 2 diabetes, triple therapy with once-daily dapagliflozin 5 mg, saxagliptin 5 mg, and metformin significantly improved glycemic control vs dual therapy with either agent added to metformin. In <5.0% and 5.8% of patients with triple therapy, urinary tract/genital infections and hypoglycemia occurred, so it was generally well tolerated.